# EDGAR Filing Document

**Accession Number:** 0002029039
**File Stem:** 0001493152-25-017378
**Filing Date:** 2025-10
**Character Count:** 10641
**Document Hash:** fc70c1b9290fb3ebb966f471ae921a13
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-017378.hdr.sgml**: 20251008

**ACCESSION NUMBER**: 0001493152-25-017378

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20251008

**FILED AS OF DATE**: 20251008

**DATE AS OF CHANGE**: 20251008

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nasus Pharma Ltd
- **CENTRAL INDEX KEY:** 0002029039
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 516022712
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42796
- **FILM NUMBER:** 251381317

**BUSINESS ADDRESS:**
- **STREET 1:** 29 HARAKEVET ST
- **CITY:** TEL AVIV - YAFO
- **STATE:** L3
- **ZIP:** 6618003
- **BUSINESS PHONE:** 972 54-255-3956

**MAIL ADDRESS:**
- **STREET 1:** 29 HARAKEVET ST
- **CITY:** TEL AVIV - YAFO
- **STATE:** L3
- **ZIP:** 6618003

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of October 2025** 

**Commission File Number: 001-42796**

**Nasus Pharma Ltd.**

**Yigal Alon 65**

**Tel Aviv, Israel 6744317**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**<u>CONTENTS</u>**

On October 6, 2025, Nasus Pharma Ltd. (the "Company") extended its collaboration with AptarGroup, Inc. and its affiliates through the execution of a series of agreements designed to advance the development and commercialization of the Company's intranasal Epinephrine program. The Company and AptarGroup Inc. have a history of collaboration dating back to 2019.

On October 6, 2025, the Company and AptarGroup, Inc. ("Aptar") entered into a Termination and Settlement Agreement (the "Termination Agreement") to: (i) terminate that certain Master Services Agreement by and between the Company and Aptar entered into on September 6, 2019 (the "2019 Aptar MSA"); (ii) terminate the schedules of work relating to Naloxone and Epinephrine entered into on September 6, 2019 and April 20, 2020, respectively; and (iii) resolve and settle outstanding disputes between the parties related to the 2019 Aptar MSA. In addition, on October 6, 2025, the Company and Aptar France S.A.S. ("Aptar France") entered into a new master services agreement (the "2025 Aptar MSA"), a schedule of work relating to the Company's Epinephrine program (the "2025 SOW"), and a short-form supply agreement (the "Supply Agreement").

***2025 MSA***

The 2025 Aptar MSA replaces the 2019 Aptar MSA and updates terms and conditions under which Aptar will provide development, analytical, regulatory, and consulting services to the Company, including services enumerated in schedules of work signed by the parties for fees set forth in such schedules.

The 2025 Aptar MSA includes customary provisions regarding confidentiality, intellectual property, indemnification, and termination rights. The 2025 Aptar MSA remains in effect until the later date of five years from the signing date, or until the services are completed.

***2025 SOW***

Pursuant to the 2025 Aptar MSA, the parties entered into a schedule of work related to Epinephrine on October 6, 2025. Under the 2025 SOW, Aptar France will provide support for the development, testing, and regulatory submission of the Company's intranasal Epinephrine powder delivered through Aptar's Unit Dose Powder nasal delivery system ("UDSp") device. In consideration for such services, the Company has agreed to pay Aptar France staged fees over the next three years, milestone payments upon (i) new drug application ("NDA") submission and (ii) NDA approval, and royalties stemming from commercial sales of the intranasal Epinephrine product for a period of seven years commencing on the date of the first commercial sale.

***Supply Agreement***

On October 6, 2025, the Company and Aptar France entered into a Supply Agreement relating to the Company's Epinephrine program. The Supply Agreement provides that, subject to U.S. Food and Drug Administration approval of the underlying program, Aptar France will exclusively supply the Company with UDSp devices, with the Company committing to purchase 100% of its requirements from Aptar France for use in its products for Epinephrine. The Supply Agreement has an initial term of five years, is renewable for two years, and sets forth pricing on a per-component basis.

***Press Release***

On October 8, 2025, the Company issued a press release titled "Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program," a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

**<u>EXHIBIT INDEX</u>**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release issued on October 8, 2025 by Nasus Pharma Ltd. titled "Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program".](ex99-1.htm) |

---

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NASUS PHARMA LTD.** | **NASUS PHARMA LTD.** |
| Date: October 8, 2025 | By: | */s/ Dan Teleman* |
|  | Name: | Dan Teleman |
|  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program**

 

*Strategic collaboration with leading global manufacturer of drug delivery systems strengthens NS002's clinical and commercial roadmap with end-to-end development support and manufacturing infrastructure*

TEL AVIV, Israel, October 8, 2025 — Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the execution of comprehensive agreements with Aptar France S.A.S. and AptarGroup, Inc. (collectively, "Aptar"), a leading global manufacturer of drug delivery systems, to support the ongoing clinical development and planned commercialization of NS002, Nasus Pharma's intranasal powder epinephrine product candidate.

"This collaboration represents a significant milestone for Nasus Pharma and for our NS002 program," said Dan Teleman, Chief Executive Officer of Nasus Pharma. "Through this collaboration, Nasus Pharma will secure a commercially proven Unit Dose System technology, providing us with a validated dosing infrastructure. This strategic relationship allows us to benefit from established regulatory pathways, manufacturing capabilities and supply chain, accelerating NS002's path to market while reducing development risks."

The collaboration establishes a comprehensive framework to support the development of NS002 through regulatory submissions with both the U.S. Food and Drug Administration (the "FDA") and the European Medicines Agency (the "EMA"). This strategic relationship provides Nasus with access to Aptar's technical expertise and manufacturing capabilities to advance NS002 through current clinical development to commercialization in alignment with Nasus Pharma's timeline and objectives.

**About Nasus Pharma**

Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus's intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal ("PBI") technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity's rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on <u>Twitter (X)</u> or <u>Linkedin</u>.

**Forward Looking Statements**

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including, among other things: statements regarding the development and commercialization of NS002; the potential benefits of the collaboration with Aptar; the potential market opportunity for NS002; and that the collaboration with Aptar is accelerating NS002's path to market while reducing development risks. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company's current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Company's prospectus related to filed with the U.S. Securities and Exchange Commission dated August 12, 2025. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

**Company Contact**

Nasus Pharma Ltd.<br> info@nasuspharma.com

**Investor Contact**

Arx Investor Relations<br> North American Equities Desk<br> nasus@arxhq.com